Eli Lilly inks drug R&D deal with Chi-Med

Eli Lilly has struck a development deal with the research arm of Hutchison China-Meditech that is worth up to $29 million in milestones for each new drug candidate developed from its library of herbal remedies. The partnership marks another step forward for biotechnology R&D in China, as local companies strike up new deals with drug developers around the world. In addition to the milestones, Chi-Med is pocketing an undisclosed upfront fee along with payments to support the research, which will initially focus on oncology and inflammation. Some analysts say the deal should be a boon to China's drug development industry, which has been afflicted by a series of scandals.

- see this release
- read the article from The Telegraph

ALSO: What do you do with a booming antidepressant? Broaden its scope, of course. Eli Lilly has filed for FDA approval to sell Cymbalta as a fibromyalgia remedy. FiercePharma

Related Articles:
Merck KGaA inks deal with China's Chi-Med. Report
China pushes drug development as R&D soars. Report
China drug czar executed for corruption. Report
China to overhaul drug safety regulations. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.